光疗联合化学免疫治疗在弥漫性大 B 细胞淋巴瘤中的研究进展

苏娜 查(内蒙古医科大学，中国;)
丽梅 李(内蒙古自治区人民医院，中国;海南医科大学第二附属医院，中国;)
艳敏 李(内蒙古科技大学包头医学院，中国;)

摘要

弥漫大 B 细胞淋巴瘤（DLBCL）作为最常见的非霍奇金淋巴瘤（NHL），其高度异质性和强侵袭性对人类健康构成严重威胁。当前，化疗免疫治疗作为一线方案，虽能使60%~70%患者临床治愈，但仍有 30%~40%患者面临复发或疾病进展难题。在针对复发难治 DLBCL 患者的治疗探索中，光疗联合化学免疫治疗展现出独特优势，二者协同作用不仅能增强对肿瘤细胞的杀伤效力，还可有效抑制肿瘤复发，为改善这部分患者的预后带来新希望。因此，深入探究光疗联合化学免疫治疗在 DLBCL 中的作用机制、疗效评估以及临床应用等方面的研究进展具有重要意义，本文将对此进行全面综述，以期为该领域的进一步发展提供参考依据。

关键词

光疗；化学免疫治疗；联合治疗；弥漫性大B细胞淋巴瘤

参考

SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J]. Blood, 2016, 127(20): 2375-90.

李小秋李, 高子芬, 周小鸽, 朱雄增,. 中国淋巴瘤亚型分布:国内多中心性病例10002例分析 [J]. 诊断学理论与实践, 2012, 11(02): 111-5.

SUN F, FANG X, WANG X. Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma [J]. Anticancer Agents Med Chem, 2019, 19(17): 2047-59.

GHIELMINI M, VITOLO U, KIMBY E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) [J]. Ann Oncol, 2013, 24(3): 561-76.

PFREUNDSCHUH M, KUHNT E, TRüMPER L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group [J]. Lancet Oncol, 2011, 12(11): 1013-22.

ZHAO L, ZHANG X, WANG X, et al. Recent advances in selective photothermal therapy of tumor [J]. J Nanobiotechnology, 2021, 19(1): 335.

BEIK J, ABED Z, GHOREISHI F S, et al. Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications [J]. J Control Release, 2016, 235: 205-21.

SHI X, ZHANG C Y, GAO J, et al. Recent advances in photodynamic therapy for cancer and infectious diseases [J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2019, 11(5): e1560.

LI X, LOVELL J F, YOON J, et al. Clinical development and potential of photothermal and photodynamic therapies for cancer [J]. Nat Rev Clin Oncol, 2020, 17(11): 657-74.

ASSOULINE S. Subcutaneous rituximab-a meaningful advance in care [J]. Lancet Haematol, 2017, 4(6): e248-e9.

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609 [J]. Blood, 2021, 137(13): 1844.

TARIQ A, AZIZ M T, MEHMOOD Y, et al. Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas [J]. Asian Pac J Cancer Prev, 2018, 19(5): 1181-4.

LI Z, JIANG W, ZHOU H, et al. Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial [J]. J Immunother Cancer, 2024, 12(10).

VASSILAKOPOULOS T P, PAPAGEORGIOU S G, ANGELOPOULOU M K, et al. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies [J]. Ann Hematol, 2021, 100(9): 2279-92.

GARG A D, AGOSTINIS P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses [J]. Photochem Photobiol Sci, 2014, 13(3): 474-87.

WALLING H W, FOSKO S W, GERAMINEJAD P A, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management [J]. Cancer Metastasis Rev, 2004, 23(3-4): 389-402.

ADAMEK M, KAWCZYK-KRUPKA A, MOSTOWY A, et al. Topical ALA-PDT modifies neutrophils’ chemiluminescence, lymphocytes’ interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies A clinical study [J]. Photodiagnosis Photodyn Ther, 2005, 2(1): 65-72.

PELLEGRINI C, ORLANDI A, COSTANZA G, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments [J]. PLoS One, 2017, 12(8): e0183415.

THEODORAKI M N, LORENZ K, LOTFI R, et al. Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer [J]. Photodiagnosis Photodyn Ther, 2017, 19: 194-201.

CAO J, QI J, LIN X, et al. Biomimetic Black Phosphorus Nanosheet-Based Drug Delivery System for Targeted Photothermal-Chemo Cancer Therapy [J]. Front Bioeng Biotechnol, 2021, 9: 707208.

HE C, DUAN X, GUO N, et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy [J]. Nat Commun, 2016, 7: 12499.

DUAN X, CHAN C, GUO N, et al. Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer [J]. J Am Chem Soc, 2016, 138(51): 16686-95.

LI L, CHEN D, ZHENG K, et al. Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel [J]. ACS Appl Mater Interfaces, 2020, 12(4): 4221-30.

JAQUE D, MARTíNEZ MAESTRO L, DEL ROSAL B, et al. Nanoparticles for photothermal therapies [J]. Nanoscale, 2014, 6(16): 9494-530.

蒋曼, 郭君妍, 杜仲, et al. 靶向CD47/SIRPα信号轴免疫疗法联合治疗策略在恶性肿瘤治疗中的应用及其作用机制研究进展[J]. 山东医药, 2024, 64(09): 104-7.

ZHU D, FAN F, HUANG C, et al. Bubble-generating polymersomes loaded with both indocyanine green and doxorubicin for effective chemotherapy combined with photothermal therapy [J]. Acta Biomater, 2018, 75: 386-97.

LONG Y, FAN J, ZHOU N, et al. Biomimetic Prussian blue nanocomplexes for chemo-photothermal treatment of triple-negative breast cancer by enhancing ICD [J]. Biomaterials, 2023, 303: 122369.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i1.23406